All News

RheumNow Podcast square

EULAR 2023 Notes from Milan (6.09.2023)

Jack Cush, MD

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Read Article
question-mark-1872634_640.jpg

Combining a Tyk2 inhibitor with a JAKi in RA?

Janet Pope, MD, MPH, FRCPC

At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.

Read Article
Hands holding shingles sign

Zoster protection for JAK inhibitor patients appears achievable

David Liew, FRACP

One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.

Read Article
sperm

Methotrexate - an old trusted friend who deserves better

Antoni Chan, MD, PhD

Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.

Read Article
Magnifying glass

Clinically suspect arthralgias: justified or artefact?

David Liew, FRACP

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.

Read Article
Puzzle pieces

Are T cells the missing link in pre-clinical RA?

Aurelie Najm, MD, PhD

T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA. 

Read Article
JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular Risks Dr. Antoni Chan discusses abstracts OP0132, POS0831, and OP0133 presented at EULAR 2023 in Milan, Italy. https://t.co/ApLaPf7uKP https://t.co/nbZgwIlHyb

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept: is there a role before RA hits? Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy. https://t.co/XJXabAULhn https://t.co/Hv93HKolKH

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Zoster Management and Vaccination Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy. https://t.co/eOhXzw3Epy https://t.co/h3NoDggg5x

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate - an old trusted friend who deserves better MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice. https://t.co/rSHsysJQ46 https://t.co/OKfBiMlqyg

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis, Radiomics and Interstitial Lung Disease Drs. Antoni Chan and Vincenzo Venerito discuss abstracts OP0127 and POS0855 presented at EULAR 2023 in Milan, Italy. https://t.co/SuMMrkwfvk https://t.co/hSSPKIW4Os

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA is Actually Difficult to Define Dr. Janet Pope discusses abstract OP0134 presented at EULAR 2023 in Milan, Italy. https://t.co/0J9mH9n8jJ https://t.co/JT1hGp2S5w

Links:

Dr. John Cush RheumNow ( View Tweet)
Are T cells the missing link in pre-clinical RA? T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA. Dr.Najm ( @AurelieRheumo ) shares #EULAR23 presentations on this topic. https://t.co/qVyDp6Gs2y https://t.co/mqxNLIxShd

Links:

Dr. John Cush RheumNow ( View Tweet)
RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly

Links:

Dr. John Cush RheumNow ( View Tweet)
AI in RA: the story grows along the patient pathway The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA. https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints ( View Tweet)
The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
Dr. Antoni Chan synovialjoints ( View Tweet)
Better at Predicting RA from MRI: Humans or Computers? https://t.co/xRVatfiRKS https://t.co/Gwypq8lcdl

Links:

Dr. John Cush RheumNow ( View Tweet)
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
Bella Mehta bella_mehta ( View Tweet)
Abstracts talking about #RA and JAKs and Biologic comparisons Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below @RheumNow https://t.co/jl5S4fLq19
Bella Mehta bella_mehta ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×